Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARDOXSO for COVID-19 ARDS/NCP
NCT04798716Phase 2Unknown
- Sponsor
- Avem Health Partners
- Start
- Sep 2023
- Primary completion
- Sep 2024
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of mesenchymal stem cell-derived exosomes in coronavirus disease 2019 (COVID-19), acute respiratory distress syndrome (ARDS), viral pneumonia, sponsored by Avem Health Partners. Status: unknown.
02
Drugs
mesenchymal stem cell-derived exosomes
03
Conditions
coronavirus disease 2019 (COVID-19)acute respiratory distress syndrome (ARDS)viral pneumonia
Beyond the preview
Go deeper on NCT04798716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798716.